Abstract
Background
The TNM staging system is far from perfect in predicting the survival of individual cancer patients because only the gross anatomy is considered. The survival rates of the patients who have the same TNM stage disease vary across a wide spectrum. This study aimed to develop a nomogram that incorporates other clinicopathologic factors for predicting the overall survival (OS) of non-metastatic nasopharyngeal carcinoma (NPC) patients after curative treatments.
Methods
We retrospectively collected the clinical data of 1520 NPC patients who were diagnosed histologically between November 2000 and September 2003. The clinical data of a separate cohort of 464 patients who received intensity-modulated radiation therapy (IMRT) between 2001 and 2010 were also retrieved to examine the extensibility of the model. Cox regression analysis was used to identify the prognostic factors for building the nomogram. The predictive accuracy and discriminative ability were measured using the concordance index (c-index).
Results
We identified and incorporated 12 independent clinical factors into the nomogram. The calibration curves showed that the prediction of OS was in good agreement with the actual observation in the internal validation set and IMRT cohort. The c-index of the nomogram was statistically higher than that of the 7th edition TNM staging system for predicting the survival in both the primary cohort (0.69 vs. 0.62) and the IMRT cohort (0.67 vs. 0.63).
Conclusion
We developed and validated a novel nomogram that outperformed the TNM staging system in predicting the OS of non-metastatic NPC patients who underwent curative therapy.
Keywords: Nasopharyngeal carcinoma, Nomogram, Prognosis
Background
Nasopharyngeal carcinoma (NPC) is relatively common among patients living in the Far East and their descendants who have migrated abroad [1, 2]. NPC in these populations is associated with Epstein–Barr virus (EBV) infection, which is rare in NPC patients in other parts of the world [3]. EBV-associated NPC has an increased tendency to metastasize to regional lymph nodes and distant sites. Radiotherapy remains the backbone of care in non-metastatic NPC patients, along with various combinations with chemotherapy, including induction, concomitant, and adjuvant chemotherapy [4].
To date, the American Joint Committee on Cancer (AJCC) TNM classification has been the most widely used staging system to estimate the prognosis and guide treatment options [5]. However, the TNM staging system is far from perfect because it only considers the tumor size and extension (T stage) and node involvement (N stage) without considering other factors with prognostic values, such as clinicopathologic factors, treatment-related factors, and tumor markers. In addition, the patient survival is significantly altered after curative therapy, such as surgery and radiotherapy. Therefore, a more accurate prediction of the survival is required in clinical practice.
In recent years, a novel prognostic model, called a nomogram, has proved a reliable model for cancer prognosis prediction [6–8]. Nomograms incorporate assessable variables through weighing their respective significance to the survival and function as a simple tool for individual survival prediction [9]. However, no nomograms have been developed for NPC. Therefore, based on a large cohort in our center, we aimed to establish a nomogram for individual survival prediction of NPC patients without distant metastasis who had undergone curative therapy. In addition, a cohort of patients who received intensity-modulated radiation therapy (IMRT) was also included for validation to test whether this nomogram could be applied to predict survival of these patients.
Patients and methods
Patient selection and data processing
Patients with histologically proven NPC treated between November 2000 and September 2003 at Sun Yat-sen University Cancer Center were examined. The patients with AJCC stage I–IVb NPC who had undergone curative treatments (including radiotherapy alone and radiotherapy in combination with either adjuvant chemotherapy or neoadjuvant chemotherapy or both) were included. An independent cohort of patients who underwent IMRT at the same institution between February 2001 and August 2010 was also included. Patients who had distant metastasis or missing data on important variables were excluded. Ethical approval was obtained from our center through the Institutional Review Board.
Clinical data were retrieved, including the age; sex; history of smoking and alcohol consumption; pathologic data [histological type and pathologic tumor (T), node (N), and metastasis (M) statuses]; treatment-related factors (radiation dose and access to neoadjuvant, concomitant, or adjuvant chemotherapy); and serological factors [hemoglobin count, platelet count, neutrophil count, lymphocyte count, neutrophil to lymphocyte ratio (NLR), titers of immunoglobulin A against Epstein–Barr virus viral capsid antigen (VCA-IgA), immunoglobulin A against Epstein–Barr virus viral early antigen (EA-IgA), and anti-DNase, and serum levels of lactate dehydrogenase (LDH) and alkaline phosphatase (ALP)].
Follow-up data for all patients were obtained from their most recent medical review, which consisted of scheduled clinical examination and assessment of chest X-ray photograms, chest or abdominal computed tomography scans, and head and neck magnetic resonance imaging every 3 months during the first 2 years after primary treatment and every 6 months thereafter, as well as the survival status every 3 months, which was evaluated by the follow-up team. The last follow-up was carried out in October 2014. Clinical staging was performed according to the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) TNM staging system (2009 version).
Continuous variables were transformed into categorical variables, and the cutoffs of all variables were recognized with the largest χ2 value in the log-rank test using a Cut-Point Optimization Tool (X-Tile, Yale University, New Haven, CT, USA) [10]. The normal range of body mass index (BMI) was set at 20–26 kg/m2. The cutoff values for other variables were derived using X-Tile, and they were discussed and confirmed by clinical expertise as follows: age (50 years), hemoglobin (150 g/L), NLR (3.5), platelet count (300 × 109/L), ALP level (90 U/L), VCA-IgA titer (1:1280), EA-IgA titer [0, (negative vs. positive)], and anti-DNase titer (50%).
Construction and validation of the nomogram
Statistical analyses to identify independent prognostic factors were conducted with SPSS 17.0 for Windows (SPSS, Chicago, IL, USA). Considering the large sample size of this cohort and the importance of independent validation, we adopted a data-splitting method using Rv.Uniform function in SPSS to randomly assign 80% of the patients to the training set for nomogram construction and 20% to the internal validation set. Overall survival (OS) was calculated from the date of diagnosis. The OS curves were generated using the Kaplan–Meier method and were compared using the log-rank test. Covariates achieving significance at a level of P < 0.05 were entered into the Cox regression model for multivariate analyses. Based on the results from multivariate analysis, a nomogram was formulated using R2.14.1 (http://www.r-project.org/) with the survival and rms package, which was based on the theory by Harrel et al. [11]. A final model was selected using a backward stepdown process, which incorporated Akaike’s information criterion as the stopping rule [12].
The derived scores were divided into the 25th, 50th, 75th, and 100th percentile to subgroup the patients. Calibration of the nomogram for the 1-, 3-, and 5-year OS was performed by comparing the median predicted OS with the actual OS from observed Kaplan–Meier estimates. The model performance for predicting the outcome was evaluated by calculating the concordance index (c-index) [13]. The value of the c-index ranged from 0.5 to 1.0, which indicates random chance to a perfect ability to correctly discriminate between the outcome and model.
Performance of the nomogram beyond the TNM staging system
We sought to evaluate the independent discrimination ability of the nomogram beyond the standard TNM staging. Kaplan–Meier OS curves of patient subgroups were delineated.
Results
Clinicopathologic characteristics of patients in the primary cohort
A total of 1520 patients with stage I–IVb NPC who had undergone at least radiotherapy in the primary cohort were eligible for final analysis, with 1036 deaths in a median follow-up of 86.6 months (range 1.4–115.0 months). The predominant histological type was World Health Organization (WHO) type III. Most of the included patients received conventional radiotherapy. Of the 1520 patients, 1216 (80%) were assigned to the training set, and 304 (20%) to the internal validation set. An independent cohort of 464 patients who underwent IMRT was selected, with 376 events in a median follow-up of 86.1 months (range 29.2–133.0 months). The clinicopathologic features of patients in the training set, internal validation set, and IMRT cohort are summarized in Table 1.
Table 1.
Demographic and clinicopathologic characteristics of non-metastatic nasopharyngeal carcinoma patients in the training set, internal validation set, and IMRT cohort
| Variable | Primary cohort [cases (%)] | IMRT cohort [cases (%)] | ||
|---|---|---|---|---|
| Total | Training set | Validation set | ||
| Total | 1520 | 1216 | 304 | 464 |
| Sex | ||||
| Male | 1161 (76.4) | 922 (75.8) | 239 (78.6) | 361 (77.8) |
| Female | 359 (23.6) | 294 (24.2) | 65 (21.4) | 103 (22.2) |
| Age (years) | ||||
| <50 | 977 (64.3) | 769 (63.2) | 208 (68.4) | 345 (74.4) |
| ≥50 | 543 (35.7) | 447 (36.8) | 96 (31.6) | 119 (25.6) |
| Smoking history | ||||
| No | 789 (51.9) | 630 (51.8) | 159 (52.3) | 271 (58.4) |
| Yes | 731 (48.1) | 586 (48.2) | 145 (47.7) | 193 (41.6) |
| Alcohol consumption | ||||
| No | 1282 (84.3) | 1030 (84.7) | 252 (82.9) | 387 (83.4) |
| Yes | 238 (15.7) | 186 (15.3) | 52 (17.1) | 77 (16.6) |
| BMI (kg/m2) | ||||
| >26 | 210 (13.8) | 174 (14.3) | 36 (11.8) | 150 (32.3) |
| 20–26 | 949 (62.4) | 755 (62.1) | 194 (63.8) | 312 (67.2) |
| <20 | 361 (23.8) | 287 (23.6) | 74 (24.3) | 2 (0.4) |
| Hemoglobin level (g/L) | ||||
| >150 | 498 (32.8) | 399 (32.8) | 99 (32.6) | 186 (40.1) |
| ≤150 | 1022 (67.2) | 817 (67.2) | 205 (67.4) | 278 (59.9) |
| NLR | ||||
| <3.5 | 1129 (74.3) | 906 (74.5) | 223 (73.4) | 384 (82.8) |
| ≥3.5 | 391 (25.7) | 310 (25.5) | 81 (26.6) | 80 (17.2) |
| Platelet count (×109/L) | ||||
| <300 | 1251 (82.3) | 1000 (82.2) | 251 (82.6) | 408 (87.9) |
| ≥300 | 269 (17.7) | 216 (17.8) | 53 (17.4) | 56 (12.1) |
| LDH level (U/L) | ||||
| <190 | 897 (59.0) | 717 (59.0) | 180 (59.2) | 352 (75.9) |
| 190–240 | 399 (26.3) | 315 (25.9) | 84 (27.6) | 80 (17.2) |
| >240 | 224 (14.7) | 184 (15.1) | 40 (13.2) | 32 (6.9) |
| ALP level (U/L) | ||||
| <90 | 1227 (80.7) | 978 (80.4) | 249 (81.9) | 401 (86.4) |
| ≥90 | 293 (19.3) | 238 (19.6) | 55 (18.1) | 63 (13.6) |
| Histological type | ||||
| WHO I | 6 (0.4) | 5 (0.4) | 1 (0.3) | 1 (0.2) |
| WHO II | 102 (6.7) | 78 (6.4) | 24 (7.9) | 41 (8.8) |
| WHO III | 1412 (92.9) | 1133 (93.2) | 279 (91.8) | 422 (90.9) |
| T stage | ||||
| T1 | 262 (17.2) | 198 (16.3) | 64 (21.1) | 86 (18.5) |
| T2 | 746 (49.1) | 603 (49.6) | 143 (47.0) | 119 (25.6) |
| T3 | 267 (17.6) | 213 (17.5) | 54 (17.8) | 191 (41.2) |
| T4 | 245 (16.1) | 202 (16.6) | 43 (14.1) | 68 (14.7) |
| N stage | ||||
| N0 | 419 (27.6) | 337 (27.7) | 82 (27.0) | 116 (25.0) |
| N1 | 642 (42.2) | 510 (41.9) | 132 (43.4) | 193 (41.6) |
| N2 | 408 (26.8) | 326 (26.8) | 82 (27.0) | 144 (31.0) |
| N3 | 51 (3.4) | 43 (3.5) | 8 (2.6) | 11 (2.4) |
| TNM stage | ||||
| I | 79 (5.2) | 60 (4.9) | 19 (6.3) | 43 (9.3) |
| II | 638 (42.0) | 511 (42.0) | 127 (41.8) | 113 (24.4) |
| III | 515 (33.9) | 408 (33.6) | 107 (35.2) | 231 (49.8) |
| IV | 288 (18.9) | 237 (19.5) | 51 (16.8) | 77 (16.6) |
| VCA-IgA titer | ||||
| <1:1280 | 1275 (83.9) | 1013 (83.3) | 262 (86.2) | 420 (90.5) |
| ≥1:1280 | 245 (16.1) | 203 (16.7) | 42 (13.8) | 44 (9.5) |
| EA-IgA | ||||
| Negative | 334 (22.0) | 272 (22.4) | 62 (20.4) | 127 (27.4) |
| >0 | 1186 (78.0) | 944 (77.6) | 242 (79.6) | 337 (72.6) |
| Anti-DNase (%) | ||||
| ≤50 | 516 (33.9) | 407 (33.5) | 109 (35.9) | 221 (47.6) |
| >50 | 1004 (66.1) | 809 (66.5) | 195 (64.1) | 205 (44.2)a |
| Neoadjuvant chemotherapy | ||||
| Yes | 997 (65.6) | 800 (65.8) | 197 (64.8) | 304 (65.5) |
| No | 523 (34.4) | 416 (34.2) | 107 (35.2) | 160 (34.5) |
| Concomitant chemotherapy | ||||
| Yes | 1171 (77.0) | 933 (76.7) | 238 (78.3) | 145 (31.3) |
| No | 349 (23.0) | 283 (23.3) | 66 (21.7) | 319 (68.7) |
| Adjuvant chemotherapy | ||||
| Yes | 1513 (99.5) | 1210 (99.5) | 303 (99.7) | 445 (95.9) |
| No | 7 (0.5) | 6 (0.5) | 1 (0.3) | 19 (4.1) |
| Radiation dose (Gy) | ||||
| ≤75 | 1329 (87.4) | 1059 (87.1) | 270 (88.8) | 240 (51.7) |
| >75 | 191 (12.6) | 157 (12.9) | 34 (11.2) | 224 (48.3) |
IMRT intensity-modulated radiation therapy; BMI body mass index; NLR neutrophil–lymphocyte ratio; LDH lactate dehydrogenase; ALP alkaline phosphatase; WHO World Health Organization; VCA-IgA immunoglobulin A against Epstein–Barr virus viral capsid antigen; EA-IgA immunoglobulin A against Epstein–Barr virus viral early antigen
aThe data of 38 patients were missing
Independent prognostic factors in the training set
The data from the training set were used to identify prognostic factors and build the model. The results of the univariate analysis are listed in Table 2. Male gender, over 50 years old, smokers, drinkers, increased NLR (≥3.5), increased platelet count (≥300 × 109/L), increased ALP level (≥90 U/L), positive EA-IgA, high anti-DNase titer (>50%), receiving no neoadjuvant, concomitant, or adjuvant chemotherapy, and high radiation dose (>75 Gy) were all associated with poor prognosis. Baseline anemia and a high titer of VCA-IgA were probably associated with poor prognosis, but the differences were not significant. Both the pathologic T and N stages had a significant impact on OS; there was an increased risk for deaths as the stage increased. The BMI and LDH were divided into three categories. A high BMI indicated a favorable survival outcome, whereas a reverse trend was revealed for the LDH level. WHO type III was the predominant histological type and associated with the best prognosis among all three types.
Table 2.
Cox univariate and multivariate analyses of prognostic factors for the overall survival of non-metastatic nasopharyngeal carcinoma patients after treatment
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P value | HR | 95% CI | P value | |
| Sex | 0.023 | 1.228 | 1.093–1.363 | 0.163 |
| Age | <0.001 | 1.572 | 1.478–1.666 | <0.001 |
| Smoking history | 0.025 | 0.957 | 0.845–1.070 | 0.833 |
| Alcohol consumption | 0.048 | 1.056 | 0.930–1.182 | 0.279 |
| BMI | 0.014 | 1.164 | 1.087–1.241 | 0.004 |
| Hemoglobin | 0.079 | Not included in the multivariate analysis | ||
| NLR | <0.001 | 1.324 | 1.225–1.423 | 0.001 |
| Platelet count | 0.015 | 1.165 | 1.048–1.282 | 0.366 |
| LDH level | <0.001 | 1.332 | 1.273–1.391 | <0.001 |
| ALP level | 0.001 | 1.235 | 1.126–1.344 | 0.185 |
| Histological type | 0.032 | 0.986 | 0.538–1.434 | 0.082 |
| T stage | <0.001 | 1.264 | 1.212–1.316 | <0.001 |
| N stage | <0.001 | 1.457 | 1.399–1.515 | <0.001 |
| TNM stage | <0.001 | Excluded due to collinearity | ||
| VCA-IgA titer | 0.099 | Not included in the multivariate analysis | ||
| EA-IgA | 0.001 | 1.224 | 1.100–1.348 | 0.179 |
| Anti-DNase titer | 0.019 | 1.155 | 1.022–1.288 | 0.43 |
| Neoadjuvant chemotherapy | <0.001 | 1.209 | 1.111–1.308 | 0.043 |
| Concomitant chemotherapy | 0.022 | 1.167 | 1.060–1.274 | 0.424 |
| Adjuvant chemotherapy | 0.035 | 1.747 | 1.238–2.256 | 0.37 |
| Radiation dose | 0.002 | 1.415 | 1.282–1.548 | 0.009 |
HR hazard ratio; CI confidence interval. Other abbreviations as in Table 1
Variables considered significant in the univariate analyses were entered in the Cox multivariate analysis. A total of 12 variables, including sex, age, T stage, N stage, BMI, NLR, radiation dose, assess to neoadjuvant or concomitant chemotherapy, EA-IgA titer, and serum LDH and ALP levels were proved independent in the multivariate Cox regression model and were incorporated in the nomogram according to the algorithm (Table 2).
Prognostic nomogram for OS prediction
Using the data of patients in the training set, a nomogram was constructed for OS prediction (Fig. 1). Longer lines indicate greater prognostic impact of specific variables, and larger points in the nomogram indicate shorter OS. The N stage had the greatest impact on OS, which was followed by the T stage, LDH level, and age. Subsequently, the BMI, NLR, and radiation dose were also found to be important. Furthermore, other independent prognostic factors provided additional prediction value.
Fig. 1.
Prognostic nomogram for patients with non-metastatic nasopharyngeal carcinoma (NPC). BMI body mass index; NLR neutrophil–lymphocyte ratio; LDH lactate dehydrogenase; ALP alkaline phosphatase; EA-IgA immunoglobulin A against Epstein–Barr virus viral early antigen
Each subtype within the above variables was assigned a score on the point scale. By adding up the total score and locating it on the total point scale, we could easily draw a straight line down to determine the estimated probability of survival at each time point. The total scores ranged from 6 to 39. By dividing the range into five equal parts, we determined five risk subgroups of patients (scoring 0–12, 13–18, 19–24, 25–31, and ≥32).
Validation of the nomogram
The data from the internal validation set were used to validate the model. The calibration plot based on the data from the internal validation set for the probability of OS at 1, 3, and 5 years demonstrated excellent agreement between the prediction according to the nomogram and actual observation (Fig. 2a). However, the predicted OS was slightly underestimated in the IMRT cohort (Fig. 2b). In addition, the Harrel’s c-index of the established nomogram to predict the OS of all patients in the primary cohort (combining the training set and the internal validation set) was significantly higher than that of the AJCC TNM staging system (0.69 [95% confidence interval {CI}, 0.67–0.71] vs. 0.62 [95% CI, 0.60–0.64], P = 0.003). With respect to OS prediction for the IMRT cohort, the c-index of the nomogram was also numerically higher than that of the TNM staging system (0.67 [95% CI, 0.62–0.72] vs. 0.63 [95% CI, 0.58–0.78], P = 0.631).
Fig. 2.
The calibration curve for predicting overall survival (OS) of patients with non-metastatic NPC in the internal validation set (a) and intensity-modulated radiation therapy (IMRT) cohort (b). The nomogram-predicted probability of OS is plotted on the x-axis; the actual OS is plotted on the y-axis
Performance of the nomogram in predicting the cancer death risk of patients
We scored the cancer death risk of every patient and classified the patients into five subgroups with distinct prognoses. The 5 year OS rates of the five risk subgroups with risk scores of 0–12, 13–18, 19–24, 25–31, and ≥32 were 90, 82, 68, 54, and 40%, respectively. When patients in the primary cohort were grouped according to their respective TNM stages (I, II, III, and IV), the stratification by risk scores resulted in significant differences in Kaplan–Meier OS curves for patients in each stage group, except for patients in stage I (Fig. 3a). As for the IMRT cohort, this stratification also resulted in significant differences in OS, except for patients in stage IV (Fig. 3b).
Fig. 3.
Kaplan–Meier OS curves of non-metastatic NPC patients in each stage stratified by the scores of risk (0–12, 13–18, 19–24, 25–31, and ≥32) in the internal validation cohort (a) and IMRT cohort (b) (pooled log-rank test)
Discussion
In the present study, we evaluated the prognostic values of several known predictors for survival of NPC patients. The association between the clinicopathologic factors and prognosis of NPC patients has been well established in previous studies [14–21] and was then confirmed in the present study. Notably, the serum level of LDH ranked third in contributing to the prognosis of NPC patients, which followed the N and T stages. This finding called attention to the importance of the baseline LDH, which might indicates the tumor activity and tendency for metastasis in NPC patients, especially in combination with ALP level [22]. Based on these results, we established a nomogram that combined 12 significant clinical factors to visualize the prediction of the prognosis of NPC patients.
With respect to the validation methods, both internal validation and external validation are appropriate. However, internal validation, such as cross-validation and bootstrap resampling, has a theoretical probability of overinterpretation [9]. Therefore, external validation is more appropriate for examining the model applicability, e.g., using a data set from other institutions or a validation set by the data-splitting method from the same institution, especially when the sample size is large [7, 13]. In this study, we calibrated the nomogram with a validation set and an IMRT cohort from the same institution that were independent from the training set. First, the high level of agreement between the expected and actual observed OS in the splitting internal validation set demonstrated the accuracy of the nomogram. In addition, discrimination was revealed by the significantly higher c-index (an index similar to the area under the receiver-operating characteristic curves in the diagnostic test) of the nomogram compared with the TNM staging system. The distinct risk stratification of patients within the same stage illustrated the additional prognostic values of incorporating other factors.
As it conforms more to the tumor shape and minimizes the toxicity to surrounding normal tissues, IMRT has been increasingly applied and has even replaced conventional radiotherapy (CRT) in recent years [23]. Considering that patients in the training set on which the nomogram was built predominantly received CRT, we retrieved a pure cohort that was treated with IMRT. An underestimation of OS was observed for the nomogram. Additionally, the predictive accuracy (c-index) of the nomogram decreased slightly in the IMRT cohort, which was in contrast to that of the TNM staging system. This might be a result of overfit bias, which is inevitable when developing a nomogram. In addition, the patient selection periods for the primary and IMRT datasets did not completely overlap. To the best of our knowledge, the patients who underwent CRT and IMRT primarily differed in their adverse events and short-term outcomes, but they did not necessarily differ in the OS [24]. Moreover, the included variables have no mechanical association with the radiotherapy modality. Therefore, we cautiously concluded that this nomogram could project to the IMRT population according to the acceptable predictive power and accuracy.
Several previous models established for NPC also showed improved prognosis prediction of the TNM staging system by adding some functional factors [25–27]. However, the practical use of these models was restricted because they only provided stratification of risks at a population level without offering an association between the individual patient and his/her corresponding OS. In contrast, the nomogram we developed in this study could serve as both a scoring system and a visualized predicting tool, which could help physicians rapidly match a patient with his/her expected OS through a simple calculation in clinical practice. In addition, this nomogram could assist in the clinical study design, balancing the prognostic background between different arms, especially for non-randomized data. This function shares a similar rationale with propensity score-matched analysis [28].
This nomogram developed for NPC patients assists clinicians in many aspects. Still, there are some limitations. First, the retrospective nature of the database might result in bias and calls for prospective validation of the model. Second, we have not yet validated the model using an external dataset from other institutes, although we are seeking further collaborations. Third, although the EBV-DNA copy number might be a strong prognostic factor, we failed to incorporate it into the nomogram because EBV-DNA was not routinely tested in our center until 2007 [29].
In conclusion, we developed and validated a novel nomogram for non-metastatic NPC patients. This nomogram provides a more accurate and precise prediction for the OS compared with the TNM staging system. This nomogram could help clinicians with decision-making and study design. In addition, this nomogram could be used to evaluate the prognosis of the IMRT population.
Authors’ contributions
Study design: WL, GS, CZ and LZ. Data collection and processing: WL, GS, YZ, GC, XW, YL, AL, SK, XY, XH, PH, YH, HZ, YT. Statistical analysis: WL, GS and LZ. Drafting: WL, GS, YZ, GC, XW and LZ. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by the National High Technology Research and Development Program of China (Grant No. 2012AA02A501 and 2012AA02A502) and Sun Yat-sen University Clinical Medical Research Project 5010 (Grant No. 20130008).
Competing interests
The authors declare that they have no competing interests.
Footnotes
Wenhua Liang, Guanzhu Shen and Yaxiong Zhang contributed equally to this work
Contributor Information
Wenhua Liang, Email: liangwh@sysucc.org.cn.
Guanzhu Shen, Email: shengzh@sysucc.org.cn.
Yaxiong Zhang, Email: zhangyx@sysucc.org.cn.
Gang Chen, Email: chengang@sysucc.org.cn.
Xuan Wu, Email: wuxuan@sysucc.org.cn.
Yang Li, Email: matsuosayuri@gmail.com.
Anchuan Li, Email: liach@sysucc.org.cn.
Shiyang Kang, Email: 397530891@qq.com.
Xi Yuan, Email: tiancaixigua@126.com.
Xue Hou, Email: houxue@sysucc.org.cn.
Peiyu Huang, Email: huangpy@sysucc.org.cn.
Yan Huang, Email: huangyan@sysucc.org.cn.
Hongyun Zhao, Email: zhaohy@sysucc.org.cn.
Ying Tian, Email: tianying@sysucc.org.cn.
Chong Zhao, Phone: +86-20-87342020, Email: zhaochong@sysucc.org.cn.
Li Zhang, Phone: +86-20-87343458, Email: zhangli6@mail.sysu.edu.cn.
References
- 1.Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 2014;33(8):381–387. doi: 10.5732/cjc.014.10086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zhang LF, Li YH, Xie SH, Ling W, Chen SH, Liu Q, et al. Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis. Chin J Cancer. 2015;34(8):350–357. doi: 10.1186/s40880-015-0018-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Young LS, Dawson CW. Epstein–Barr virus and nasopharyngeal carcinoma. Chin J Cancer. 2014;33(12):581–590. doi: 10.5732/cjc.014.10197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20(8):2038–2044. doi: 10.1200/JCO.2002.08.149. [DOI] [PubMed] [Google Scholar]
- 5.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7. Philadelphia: Lippincott-Raven; 2009. [Google Scholar]
- 6.Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29(23):3163–3172. doi: 10.1200/JCO.2010.33.1595. [DOI] [PubMed] [Google Scholar]
- 7.Wang JY, Zhu Y, Wang CF, Zhang SL, Dai B, Ye DW. A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients. Chin J Cancer. 2014;33(5):241–248. doi: 10.5732/cjc.013.10137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25(11):1316–1322. doi: 10.1200/JCO.2006.06.1218. [DOI] [PubMed] [Google Scholar]
- 9.Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi: 10.1200/JCO.2007.12.9791. [DOI] [PubMed] [Google Scholar]
- 10.Camp RL, Dolled Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi: 10.1158/1078-0432.CCR-04-0713. [DOI] [PubMed] [Google Scholar]
- 11.Harrell FE, Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985;69(10):1071–1077. [PubMed] [Google Scholar]
- 12.Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
- 13.Harrell FE., Jr . Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001. [Google Scholar]
- 14.Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, et al. Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Clin Oncol (R Coll Radiol). 2013;25(3):171–177. doi: 10.1016/j.clon.2012.10.006. [DOI] [PubMed] [Google Scholar]
- 15.Chen YP, Zhao BC, Chen C, Shen LJ, Gao J, Mai ZY, et al. Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients. Chin J Cancer. 2015;34(3):137–146. doi: 10.1186/s40880-015-0006-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kong F, Cai BZ, Chen XZ, Zhang J, Wang YM. Prognostic factors for survival of patients with nasopharyngeal carcinoma following conventional fractionation radiotherapy. Exp Ther Med. 2013;6(1):57–60. doi: 10.3892/etm.2013.1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Li G, Gao J, Tao YL, Xu BQ, Tu ZW, Liu ZG, et al. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. Chin J Cancer. 2012;31(4):197–206. doi: 10.5732/cjc.011.10283. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Cai YL, Li J, Lu AY, Zhong WM, Zheng YM, Gao JQ, et al. Prognostic significance of serum anti-Epstein–Barr virus antibodies in nasopharyngeal carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013;27(2):119–122. [PubMed] [Google Scholar]
- 19.Nakamura T, Kodaira T, Tachibana H, Tomita N, Tomoda T, Nakahara R, et al. Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors. Jpn J Clin Oncol. 2008;38(12):803–809. doi: 10.1093/jjco/hyn104. [DOI] [PubMed] [Google Scholar]
- 20.Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys. 2006;65(5):1300–1306. doi: 10.1016/j.ijrobp.2006.02.016. [DOI] [PubMed] [Google Scholar]
- 21.Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC, et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma—is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys. 2004;60(1):156–164. doi: 10.1016/j.ijrobp.2004.03.002. [DOI] [PubMed] [Google Scholar]
- 22.Wan XB, Wei L, Li H, Dong M, Lin Q, Ma XK, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer. 2013;49(10):2356–2364. doi: 10.1016/j.ejca.2013.03.008. [DOI] [PubMed] [Google Scholar]
- 23.De Neve W, De Gersem W, Madani I. Rational use of intensity modulated radiation therapy: the importance of clinical outcome. Semin Radiat Oncol. 2012;22(1):40–49. doi: 10.1016/j.semradonc.2011.09.003. [DOI] [PubMed] [Google Scholar]
- 24.Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):286–293. doi: 10.1016/j.radonc.2012.08.013. [DOI] [PubMed] [Google Scholar]
- 25.Xia WX, Zhang HB, Shi JL, Lu X, Wang L, Ye YF, et al. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification. Eur J Cancer. 2013;49(9):2152–2160. doi: 10.1016/j.ejca.2013.03.003. [DOI] [PubMed] [Google Scholar]
- 26.Chang H, Gao J, Xu BQ, Guo SP, Lu RB, Li G, et al. Haemoglobin, neutrophil to lymphocyte ratio and platelet count improve prognosis prediction of the TNM staging system in nasopharyngeal carcinoma: development and validation in 3237 patients from a single institution. Clin Oncol (R Coll Radiol). 2013;25(11):639–646. doi: 10.1016/j.clon.2013.07.004. [DOI] [PubMed] [Google Scholar]
- 27.Zhang H, Xia W, Lu X, Sun R, Wang L, Zheng L, et al. A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predicts risk of disease progression and survival of nasopharyngeal carcinoma patients. PLoS ONE. 2013;8(2):e57830. doi: 10.1371/journal.pone.0057830. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(82):757–763. doi: 10.7326/0003-4819-127-8_Part_2-199710151-00064. [DOI] [PubMed] [Google Scholar]
- 29.Chan KC. Plasma Epstein–Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer. 2014;33(12):598–603. doi: 10.5732/cjc.014.10192. [DOI] [PMC free article] [PubMed] [Google Scholar]